Administration of IL-15 peptide significantly improved left ventricular ejection fraction and reduced infarct size by 1.7-fold compared to saline in a mouse model of myocardial infarction.
Does administration of Interleukin-15 peptide improve cardiac function and reduce scar size in a mouse model of myocardial infarction?
IL-15 peptide administration demonstrates cardioprotective effects in vivo by improving left ventricular ejection fraction and reducing scar size in a mouse model of myocardial infarction.
Effect estimate: 1.7-fold reduction
p-value: p=<0.05
Interleukin-15 is a pleotropic factor, capable of modulating metabolism, survival, proliferation, and differentiation in many different cell types. The rationale behind this study relates to previous work demonstrating that IL-15 is a major factor present in stem cell extracts, which protects cardiomyocytes subjected to hypoxic stress in vitro. The objective of this current study was to assess whether administration of IL-15 peptide will also show protective effects in vivo. The data indicate that administration of IL-15 reduces cell death, increases vascularity, decreases scar size, and significantly improves left ventricular ejection fraction in a mouse model of myocardial infarction.
Ameri et al. (Mon,) conducted a other in Myocardial Infarction (n=54). Interleukin-15 (IL-15) peptide vs. 0.9% saline solution was evaluated on Infarct size (1.7-fold reduction, p=<0.05). Administration of IL-15 peptide significantly improved left ventricular ejection fraction and reduced infarct size by 1.7-fold compared to saline in a mouse model of myocardial infarction.